Company Filing History:
10 out of 505 
9 out of 1,153 
3 out of 4 
Years Active: 2012-2024
Title: Innovations and Contributions of Andras Gruber
Introduction:
Andras Gruber is an accomplished inventor based in Portland, OR, recognized for his groundbreaking contributions to the field of biomedical research. With a portfolio of 12 patents, Gruber has made significant advancements in the development of monoclonal antibodies that have the potential to change therapeutic approaches for various medical conditions.
Latest Patents:
Gruber's latest patents reflect his innovative work in the area of therapeutic antibodies. One of his notable inventions is a therapeutic factor XII antibody, which involves monoclonal antibodies that specifically bind to blood protein factor XII (FXII). These antibodies are capable of forming immune complexes with human FXII, effectively inhibiting its activity to produce safe anti-inflammatory and anti-thrombotic effects. Another significant patent is related to anti-factor XI monoclonal antibodies and their methods of use. This invention describes compositions that inhibit thrombosis without compromising hemostasis, utilizing antibodies (aXIMabs) that bind to specific epitopes on the heavy chain of human FXI. His pharmaceutical compositions leverage these anti-factor XI monoclonal antibodies, providing opportunities to treat thrombosis, reduce necessary antithrombotic agent dosages, and even treat metastatic cancer and acute inflammatory reactions.
Career Highlights:
Andras Gruber has had a distinguished career with affiliations to prestigious research institutions. He has worked at Oregon Health & Science University and Vanderbilt University, where he honed his expertise and contributed to significant research in the realm of cardiovascular and inflammatory diseases. His innovative thinking has facilitated the creation of advanced therapeutic formulations that address critical health issues.
Collaborations:
Throughout his career, Gruber has collaborated with notable colleagues in his field, including Erik Tucker and David Gailani. Their joint efforts have further propelled the research efforts in the realm of thrombosis and inflammation, leading to the development of groundbreaking therapies that carry immense clinical significance.
Conclusion:
Andras Gruber is a pivotal figure in the field of biomedical innovation. His work in developing monoclonal antibodies exemplifies his significant contributions towards creating safer and more effective therapeutic options for patients. With a robust portfolio of patents and collaborative efforts, Gruber continues to be a source of inspiration and progress in the realm of medical research.